Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment to improve
overall survival for intermediate- and high-risk localized disease as well as metastatic
disease. While ADT improves survival, it can cause significant morbidity and a decrement in
quality of life. In particular, ADT is associated with decrease in bone mineral density (BMD)
and increased risk of fracture.
Although current guidelines recommend continuous androgen deprivation therapy (CAD) as
standard therapy for high-risk disease, there has been increasing recognition of adverse
effects from CAD. Since 1986, intermittent androgen deprivation therapy (IAD) as alternative
therapeutic strategy for prostate cancer has been proposed to delay development of castration
resistance and to reduce the side effects of ADT.
While both CAD and IAD are commonly used in real clinical practice, no prior study examined
BMD change after CAD or IAD, and assessed whether bone loss would recover during
off-treatment of IAD. The investigators therefore determine the rate of change in BMD induced
by ADT (CAD versus IAD) in men with prostate cancer.